Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for the sterile manufacture of AZD1222, a COVID-19 recombinant adenovirus vaccine, to be used in clinical trials.
Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for the sterile manufacture of AZD1222, a COVID-19 recombinant adenovirus vaccine, to be used in clinical trials.
According to a June 22, 2020 press release, the terms of the agreement will see Symbiosis provide AstraZeneca with fast-track access to sterile vaccine drug product manufacturing capacity. This latest news follows from AstraZeneca’s licensing agreement with the University of Oxford for the global development, manufacture, and distribution of AZD1222 vaccine candidate, which is currently in clinical trials at multiple sites in the United Kingdom.
“Our team is immensely proud to be able to make a highly meaningful contribution to the global fight against COVID-19 and the urgent efforts to develop a successful vaccine,” said Colin MacKay, founder and CEO of Symbiosis, in the press release. “With many years of direct experience manufacturing medicines and vaccines of this nature for clinical trials and commercial markets, we are delighted to be able to leverage our expertise and competitive strengths to accelerate the development of this vaccine for AstraZeneca and to add value to the project.”
Symbiosis Pharmaceutical Services is a specialist provider of pharmaceutical and vaccine development services in Stirling, Scotland.
Source: Symbiosis
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.